HIV vaccine approach succeeds in first clinical trial
First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research
The experimental vaccine primed the immune system as the first stage in the production of broadly neutralizing antibodies.
February 3, 2021
NEW YORK and LA JOLLA, CA—A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
“This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well,” says William Schief, Ph.D., a professor and immunologist at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center (NAC), whose laboratory developed the vaccine. “With our many collaborators on the study team, we showed that vaccines can be designed to stimulate rare immune cells with specific properties, and this targeted stimulation can be very efficient in humans. We believe this approach will be key to making an HIV vaccine and possibly important for making vaccines against other pathogens.”
Schief presented the results on behalf of the study team at the International AIDS Society HIV Research for Prevention (HIVR4P) virtual conference today.
The study sets the stage for additional clinical trials that will seek to refine and extend the approach—with the long-term goal of creating a safe and effective HIV vaccine. As a next step, IAVI and Scripps Research are partnering with the biotechnology company Moderna to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells. Using mRNA technology could significantly accelerate the pace of HIV vaccine development.
HIV, which affects more than 38 million people globally, is known to be among the most difficult viruses to target with a vaccine, in large part because it constantly evolves into different strains to evade the immune system.
“These exciting findings emerge from remarkably creative, innovative science and are a testament to the research team’s talent, dedication and collaborative spirit, and to the generosity of the trial participants,” says Mark Feinberg, M.D., Ph.D., president and CEO of IAVI. “Given the urgent need for an HIV vaccine to rein in the global epidemic, we think these results will have broad implications for HIV vaccine researchers as they decide which scientific directions to pursue. The collaboration among individuals and institutions that made this important and exceptionally complex clinical trial so successful will be tremendously enabling to accelerate future HIV vaccine research.”
Learn more:
https://www.scripps.edu/news-and-events/press-room/2021/20210203-hiv-vaccine.html
https://www.scripps.edu/
https://www.iavi.org/
IAVI Media Contact
Karie Youngdahl
+1 484 343 1731
KYoungdahl@iavi.org
Scripps Research Media Contact
Kelly Quigley
+1 858 784 2036
kquigley@scripps.org
Видео HIV vaccine approach succeeds in first clinical trial канала Scripps Research
The experimental vaccine primed the immune system as the first stage in the production of broadly neutralizing antibodies.
February 3, 2021
NEW YORK and LA JOLLA, CA—A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
“This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well,” says William Schief, Ph.D., a professor and immunologist at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center (NAC), whose laboratory developed the vaccine. “With our many collaborators on the study team, we showed that vaccines can be designed to stimulate rare immune cells with specific properties, and this targeted stimulation can be very efficient in humans. We believe this approach will be key to making an HIV vaccine and possibly important for making vaccines against other pathogens.”
Schief presented the results on behalf of the study team at the International AIDS Society HIV Research for Prevention (HIVR4P) virtual conference today.
The study sets the stage for additional clinical trials that will seek to refine and extend the approach—with the long-term goal of creating a safe and effective HIV vaccine. As a next step, IAVI and Scripps Research are partnering with the biotechnology company Moderna to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells. Using mRNA technology could significantly accelerate the pace of HIV vaccine development.
HIV, which affects more than 38 million people globally, is known to be among the most difficult viruses to target with a vaccine, in large part because it constantly evolves into different strains to evade the immune system.
“These exciting findings emerge from remarkably creative, innovative science and are a testament to the research team’s talent, dedication and collaborative spirit, and to the generosity of the trial participants,” says Mark Feinberg, M.D., Ph.D., president and CEO of IAVI. “Given the urgent need for an HIV vaccine to rein in the global epidemic, we think these results will have broad implications for HIV vaccine researchers as they decide which scientific directions to pursue. The collaboration among individuals and institutions that made this important and exceptionally complex clinical trial so successful will be tremendously enabling to accelerate future HIV vaccine research.”
Learn more:
https://www.scripps.edu/news-and-events/press-room/2021/20210203-hiv-vaccine.html
https://www.scripps.edu/
https://www.iavi.org/
IAVI Media Contact
Karie Youngdahl
+1 484 343 1731
KYoungdahl@iavi.org
Scripps Research Media Contact
Kelly Quigley
+1 858 784 2036
kquigley@scripps.org
Видео HIV vaccine approach succeeds in first clinical trial канала Scripps Research
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
How close are we to eradicating HIV? - Philip A. ChanResearchers partnering with Moderna to create mRNA HIV vaccine | Your MorningHIV breakthrough at Temple University gets researchers closer to the cureMedical Animation: HIV and AIDSWhy it’s so hard to cure HIV/AIDS - Janet IwasaOxford University researchers trial new HIV vaccine | Your MorningNew HIV hope after natural suppression found in DRC group |The WorldABC 7 News at 11pm Live Segment by Justin Hinton on May 26, 2021How close is China to developing an HIV vaccine?HIV & AIDS - signs, symptoms, transmission, causes & pathologyCould the coronavirus bring us closer to an HIV vaccine? | COVID-19 SpecialGravitas: Woman in Argentina defeats Aids 'naturally'Is the new HIV Vaccine REALLY Effective?AGT Announces Progress With HIV Cure Program - ABC 7 Interview with CEO Jeff GalvinHIV Injectable drug!! First FDA approved medication for HIV that is given IM once a month!!The impact of Covid-19 on HIV care in FranceHIV Therapy in Development at American Gene Technologies - A Non-Technical OverviewWhy Is It So Difficult To Develop an HIV Vaccine?Medications Now Available That Can Prevent AIDS, Turn Disease Into Treatable ConditionHIV Cure Program Clinical Trial Update - Spring 2021